Below are the most recent publications written about "Multiple Sclerosis, Relapsing-Remitting" by people in Profiles.
-
Herranz E, Treaba CA, Barletta VT, Mehndiratta A, Ouellette R, Sloane JA, Ionete C, Babu S, Mastantuono M, Magon S, Loggia ML, Makary MM, Hooker JM, Catana C, Kinkel RP, Nicholas R, Klawiter EC, Magliozzi R, Mainero C. Characterization of cortico-meningeal translocator protein expression in multiple sclerosis. Brain. 2024 Jul 05; 147(7):2566-2578.
-
Wilken J, Traboulsee A, Nelson F, Ionete C, Kolind S, Fratto T, Kane R, Gandhi R, Rawlings AM, Roesch N, Ozog MA, DeLuca J. Longitudinal assessment of neurocognitive function in people with relapsing multiple sclerosis initiating alemtuzumab in routine clinical practice: LEM-COG study results. Mult Scler Relat Disord. 2023 May; 73:104677.
-
O'Hara BA, Gee GV, Haley SA, Morris-Love J, Nyblade C, Nieves C, Hanson BA, Dang X, Turner TJ, Chavin JM, Lublin A, Koralnik IJ, Atwood WJ. Teriflunomide Inhibits JCPyV Infection and Spread in Glial Cells and Choroid Plexus Epithelial Cells. Int J Mol Sci. 2021 Sep 10; 22(18).
-
Sato S, Buonaccorsi J, Miehm JD, Lim J, Rajala C, Khalighinejad F, Ionete C, Kent JA, van Emmerik REA. Non-ambulatory measures of lower extremity sensorimotor function are associated with walking function in Multiple Sclerosis. Mult Scler Relat Disord. 2021 Aug; 53:103051.
-
Bass AD, Arroyo R, Boster AL, Boyko AN, Eichau S, Ionete C, Limmroth V, Navas C, Pelletier D, Pozzilli C, Ravenscroft J, Sousa L, Tintor? M, Uitdehaag BMJ, Baker DP, Daizadeh N, Choudhry Z, Rog D. Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years. Mult Scler Relat Disord. 2021 Apr; 49:102717.
-
Herman JA, Khalighinejad F, York K, Radu I, Berrios Morales I, Ionete C, Hemond CC. A real-world cohort analysis of alemtuzumab outcomes in relapsing multiple sclerosis. Mult Scler Relat Disord. 2021 Jan; 47:102619.
-
Erlich-Malona N, Cahill J, Chaudhry S, Martin J, Rizvi S. Cardiac sarcoidosis requiring ICD placement and immune thrombocytopenia following alemtuzumab treatment for multiple sclerosis. Mult Scler Relat Disord. 2021 Jan; 47:102599.
-
Steingo B, Al Malik Y, Bass AD, Berkovich R, Carraro M, Fern?ndez ?, Ionete C, Massacesi L, Meuth SG, Mitsikostas DD, Pardo G, Simm RF, Traboulsee A, Choudhry Z, Daizadeh N, Compston DAS. Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223. J Neurol. 2020 Nov; 267(11):3343-3353.
-
Sato S, Lim J, Miehm JD, Buonaccorsi J, Rajala C, Khalighinejad F, Ionete C, Kent JA, van Emmerik REA. Rapid foot-tapping but not hand-tapping ability is different between relapsing-remitting and progressive multiple sclerosis. Mult Scler Relat Disord. 2020 Jun; 41:102031.
-
Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulovic J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI. Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019 09; 18(9):845-856.